We understand that development of commercial strategies must be done with awareness and understanding of your “end game” expectations.
We are experienced in developing corporate strategy, as well as providing a variety of complimentary transaction advisory services:
Working with venture capital and private equity firms in the commercial assessment of investment opportunities
Assisting management teams with the project management and negotiation of asset divestitures and out-licensing transactions in conjunction with our New Product Planning services
Assisting emerging biopharma company boards and management teams with the development and validation of strategic plans, aligning business activities with financing options and shareholder liquidity expectations
Participating in the efficient and fairly-valued structured acquisitions of a client’s “tail” or non-strategic products as an alternative to a distracting or disruptive auction process
While many firms promise to deliver the resources and expertise necessary to develop and implement a cohesive plan, far fewer are willing to put their reputations on the line and execute these plans on behalf of their clients.
Skysis professionals can take on general management responsibilities on either a fully- or partially-dedicated basis. Assignments can range from a few months to multiple years, giving clients the flexibility to transition activities internally when the time is right.
Learn more about Skysis’ comprehensive, detailed, and fully integrated commercialization planning framework. This customized deliverable includes cost roll-up across all initiatives, with a revenue forecast to generate financial scenarios (i.e. P&L, NPV, Cash Flow, etc.) from starting point to 5 years post launch.
Is it time to start planning for loss of exclusivity or LOE? If your branded product faces patent expiry in the next 5 years or less, the timing is now for developing an LOE strategy. Let Skysis help you research options and design and implement a plan that minimizes generic erosion and capitalizes on specific generic opportunities.
Introducing “Two Thumbs Up,” a comprehensive offering from Skysis that enables biopharmaceutical professionals to confidently make the go/no-go decision relative to a drug’s commercial potential, regulatory pathway, and clinical development feasibility.
We measure value based on our ability to integrate competitive insights into a client’s brand planning and corporate strategy development. Skysis Competitive Intelligence professionals have earned advanced degrees and average twenty years’ experience in the pharmaceutical industry and/or medical field. Customize your team, choosing from MDs with clinical research experience, PhDs with clinical and commercial industry experience, and PharmDs & MBAs with significant competitive intelligence experience.